Clinical trials: Plaque, Amyloid
Parkinson's Disease
Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients
The primary aim of this study is to compare regional amyloid burden in Parkinson's disease (PD) to normal control subjects. We hypothesize that there will be significant differences in overall amyloid burden in PD patients…
- Trial name
- NCT00857532
- Testing
- florbetapir F 18
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Avid Radiopharmaceuticals
Plaque
Multi-Media Parent-based Intervention to Promote Dental Hygiene Among Young Children: BeReady2Smile II
"BeReady2Smile (BR2S)", based on successful results from the Phase I SBIR feasibility/usability research of the prototype, is a coordinated oral health prevention intervention program that provides empirically-supported…
- Trial name
- BR2S-II (NCT05321719)
- Testing
- Comparison Condition, BeReady2Smile video only, BeReady2Smile video and BeReady2Smile app completely self-guided
- Where
- United States
- Volunteers
- 228 people
- Sponsor
- Oregon Research Behavioral Intervention Strategies, Inc.
Alzheimer Disease
Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease
The aim of this study is to measure the effect of EGb 761® versus placebo on the ratio of the isoform of the protein precursor of beta amyloid platelets, in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00500500
- Testing
- EGb 761® (Tanakan®)
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Ipsen
Alzheimer's Disease
Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age
The study determined the safety of CNP520 in healthy elderly over 3 months. Data relevant for Pharmacokinetic/Pharmacodynamic modeling were obtained in order to define the target dose in subsequent efficacy studies.
- Trial name
- NCT02576639
- Testing
- CNP520
- Where
- 11 sites in United States, Belgium and 3 more
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Atrophy, Geographic
Pharmacokinetic (PK) Study of GSK933776 in Healthy Volunteers
This study is intended to enable a possible transition to intramuscular (IM) or subcutaneous (SQ) administration for subsequent studies with GSK933776 by characterizing the safety, tolerability, PK and pharmacodynamic profiles…
- Trial name
- NCT02033668
- Testing
- GSK933776 for SQ administration, GSK933776 for IM administration, GSK933776 for IV administration
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Maximum Diagnostic Mass of [18Fluor]AZD4694
An Open Positron Emission Tomography Study to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease
In this study different mass of the radioligand AZD4694 will be given to patients with Alzheimer's Disease and healthy volunteers to evaluate wich Mass of AZD4694 that gives the best opportunities for following disease progress…
- Trial name
- NCT01325402
- Testing
- [18Fluor]AZD4694
- Where
- 2 sites in Sweden
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Gingival Inflammation, Plaque
Stannous Fluoride Toothpaste for Reduction and Treatment of Gingivitis
This study evaluated the efficacy of a stannous fluoride toothpaste compared to a sodium fluoride control toothpaste in reducing gingivitis, bleeding, and plaque over a 12-week period.
- Conditions
- Gingival Inflammation, Plaque, Bleeding
- Trial name
- NCT07640399
- Testing
- Sodium Fluoride Dentifrice, Stannous Fluoride Toothpaste (SnF)
- Where
- Canada
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Church & Dwight Company, Inc.
Periodontitis, Plaque, Dental
Impact of Regular Home Use of Lumoral Dual-light Photodynamic Therapy on Plaque Control and Gingival Health
This early-stage study is designed to determine the efficacy of the CE-approved, antibacterial, dual-light Lumoral method in periodontitis patients.
- Conditions
- Periodontitis, Plaque, Dental, Plaque Induced Gingivitis
- Trial name
- NCT05361590
- Testing
- Lumoral device
- Where
- Finland
- Volunteers
- 40 people
- Sponsor
- Koite Health Oy
Plaque Psoriasis
A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.
Study of effects of secukinumab 300 mg s.c. on quality of life (QoL) in psoriasis in patients with or without prior exposure to systemic therapy.
- Trial name
- PROSE (NCT02752776)
- Testing
- Secukinumab
- Where
- 215 sites in Belgium, Bulgaria and 15 more
- Volunteers
- 1,660 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
[18F]MK-3328 as a Possible Novel Positron Emission Tomography (PET) Tracer for the Detection of Brain Amyloid Plaques (MK-3328-002)
The purpose of this study is to evaluate radiolabeled [18F]MK-3328 as a PET tracer for estimating the regional distribution and extent of amyloid plaques in participants suffering from amnestic mild cognitive impairment (aMCI)…
- Trial name
- NCT01385033
- Testing
- [18F]MK-3328
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Gingivitis, Plaque
Six Week Study of Experimental Mouth Rinses: Effect on Gingivitis and Plaque
The purpose of this study is to evaluate the safety and efficacy of experimental mouth rinse formulations compared to a positive control mouth rinse and a hydroalcohol control mouth rinse for the reduction of gingivitis and…
- Trial name
- NCT04921371
- Testing
- Colgate® Cavity Protection Toothpaste, Listerine® Cool Mint®, Concept Curve Winter Series Toothbrush
- Where
- United States
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Psoriasis
Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis
Evaluate psoriasis severity and its psychosocial impact using a novel Patient Reported Outcome (the Simplified Psoriasis Index SPI) at 16 weeks, as well as long-term safety, tolerability and efficacy of secukinumab administered…
- Trial name
- IPSI-PSO (NCT02595970)
- Testing
- Secukinumab
- Where
- 17 sites in France
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Plaque, Gingivitis
Study to Investigate Toothpaste on Antibacterial Effects in the Different Regions of the Mouth
The clinical study will examine the effects of brushing with randomly assigned test toothpaste on the bacteria on the dental plaque, tongue, cheek, gum surface, and in saliva
- Trial name
- NCT07458464
- Testing
- stannous fluoride toothpaste, 0.76% Sodium Monofluorophosphate (Na MFP) toothpaste
- Where
- 2 sites in Thailand
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Colgate Palmolive
Alzheimer Disease, Amyloid
A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease
The purpose of this Master Protocol is to support multiple studies looking at safety and tolerability of different drugs in healthy participants and participants with Alzheimer's disease, and if they remove clumps of protein…
- Conditions
- Alzheimer Disease, Amyloid, Plaque, Amyloid, Healthy Volunteers
- Trial name
- NCT07787169
- Testing
- LY4405094, Florbetapir F18, Florbetaben F 18
- Where
- 18 sites in United States, China and 1 more
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease (AD)
Phase 1 Study to Evaluate the Safety and Tolerability of 8M2D in Healthy People and Alzheimer's Patients
This study is testing a new investigational drug called 8M2D to learn whether it is safe and well-tolerated in humans. 8M2D has not previously been given to people.
- Trial name
- NCT07568041
- Testing
- 8M2D
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Cenna Biosciences Inc.
Alzheimer Disease
Proof-of-concept Study of New Imaging Diagnostic in Patients With Suspected Alzheimer's Disease
This study is a Phase 1, first-in-human, multi-center study to establish safety of ADx-001 in healthy volunteers, and safety and proof of concept in patients with confirmed amyloid plaques in the brain (confirmed by amyloid…
- Trial name
- NCT05453539
- Testing
- DSPE-DOTA-Gd Liposomal Injection
- Where
- 2 sites in Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Alzeca Biosciences, Inc.
Transthyretin Amyloid Cardiomyopathy
A Research Study to Look at the Distribution and Effects of Coramitug on Amyloid Deposits in Heart Tissue Using PET/CT Imaging in People With ATTR Amyloidosis.
The study is conducted in participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a heart disease that occurs in people with the disease ATTR amyloidosis.
- Trial name
- NCT07448623
- Testing
- Coramitug
- Where
- Netherlands
- Volunteers
- 14 people
- Sponsor
- Novo Nordisk A/S
Alzheimer's Disease (AD)
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population.
- Trial name
- NCT05291234
- Testing
- ABBV-916
- Where
- 32 sites in United States
- Volunteers
- 106 people
- Sponsor
- AbbVie
Periodontitis
Regular Home Use of Dual-light Photodynamic Therapy in the Management of Chronic Periodontitis
The study is a single site, randomized clinical trial designed to determine the efficacy of the Lumoral treatment in periodontitis patients.
- Trial name
- HOPE-CP (NCT05278416)
- Testing
- Lumoral treatment -device and Lumorinse tablets
- Where
- Finland
- Volunteers
- 202 people, healthy volunteers welcome
- Sponsor
- Koite Health Oy
Alzheimer Disease
Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology
To determine the sensitivity and specificity of the visual assessment of tracer uptake in the Florbetaben PET images compared to histological verification of the presence or absence of cerebral β-amyloid in the respective…
- Trial name
- NCT01020838
- Testing
- Florbetaben (BAY94-9172)
- Where
- 19 sites in United States, Australia and 3 more
- Volunteers
- 218 people
- Sponsor
- Lantheus Biosciences Ltd.